Targeting mammalian target of rapamycin (mTOR) for health and diseases

Chi Kwan Tsang, Haiyan Qi, Leroy F. Liu, X. F.Steven Zheng

研究成果: 雜誌貢獻回顧型文獻同行評審

328 引文 斯高帕斯(Scopus)

摘要

The macrolide rapamycin is used clinically to treat graft rejection and restenosis. Mammalian target of rapamycin (mTOR) is a central controller of cellular and organism growth that integrates nutrient and hormonal signals, and regulates diverse cellular processes. New studies have linked mTOR to several human diseases including cancer, diabetes, obesity, cardiovascular diseases and neurological disorders. Recent data have also revealed that mTOR is involved in the regulation of lifespan and in age-related diseases. These findings demonstrate the importance of growth control in the pathology of major diseases and overall human health, and underscore the therapeutic potential of the mTOR pathway.

原文英語
頁(從 - 到)112-124
頁數13
期刊Drug Discovery Today
12
發行號3-4
DOIs
出版狀態已發佈 - 二月 2007
對外發佈Yes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

指紋 深入研究「Targeting mammalian target of rapamycin (mTOR) for health and diseases」主題。共同形成了獨特的指紋。

引用此